The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness. Moreover,.
Alaunos Therapeutics (NASDAQ: ) just reported results for the fourth quarter of 2023. InvestorPlace Earnings is a project that leverages data from TradeSmith…
29.01.2024 - WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) - TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of . Seite 1
432,969 Shares in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Acquired by Magnolia Capital Advisors LLC theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.